Histamine H1 Receptor Antagonists Pipeline Insight
DelveInsight’s, “Histamine H1 Receptor Antagonists - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Histamine H1 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Histamine H1 Receptor Antagonists Understanding
Histamine H1 Receptor Antagonists: Overview
Histamine and its receptors (H1R–H4R) play a crucial and significant role in the development of various allergic diseases. H1R are expressed in many cells, including mast cells, and are involved in Type 1 hypersensitivity reactions. Activation of the H1 receptor increases vascular permeability, stimulates sensory nerves of airways, and promotes chemotaxis of eosinophils, so can cause sneezing, nasal congestion and rhinorrhea. The H1 receptor is widely distributed in the periphery, notably smooth muscle, where it stimulates contraction (vasoconstriction). It is also found in the adrenal medulla, vascular endothelium and heart and throughout the CNS, including the cerebral cortex, spinal cord and cerebellum. H1R-antagonists act as highly effective inverse agonists of H1R, which reduce basal activity of the receptor and therefore are expected to interfere with the key molecular switches involved in the GPCR activation mechanism.
The companies and academics are working to assess challenges and seek opportunities that could influence Histamine H1 Receptor Antagonists R&D. The therapies under development are focused on novel approaches for Histamine H1 Receptor Antagonists.
Histamine H1 Receptor Antagonists Emerging Drugs Chapters
This segment of the Histamine H1 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Histamine H1 Receptor Antagonists Emerging Drugs
TNX-102 SL: Tonix Pharmaceuticals
TNX-102 is a multifunctional agent including antagonism of 5-HT2A, α1-adrenergic and histamine H1 receptors. TNX-102 SL is a small, rapidly-disintegrating, sublingual product candidate containing 2.8 mg of cyclobenzaprine HCl. The unique formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. The drug is in phase III clinical studies for the treatment of fibromyalgia and in Phase II studies for agitation and alcohol use disorder.
Flunarizine: Xenon Pharmaceuticals
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. The drug is being studied for the treatment-resistant childhood absence epilepsy (CAE) and potentially other neurological disorders.
Further product details are provided in the report……..
Histamine H1 Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Histamine H1 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Histamine H1 Receptor Antagonists
There are approx. 15+ key companies which are developing the Histamine H1 Receptor Antagonists. The companies which have their Histamine H1 Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase III include, Tonix Pharmaceuticals.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Histamine H1 Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Histamine H1 Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Histamine H1 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Histamine H1 Receptor Antagonists drugs.
Histamine H1 Receptor Antagonists Report Insights
- Histamine H1 Receptor Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Histamine H1 Receptor Antagonists Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Histamine H1 Receptor Antagonists drugs?
- How many Histamine H1 Receptor Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Histamine H1 Receptor Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Histamine H1 Receptor Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Histamine H1 Receptor Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?